(Bloomberg) -- GlaxoSmithKline Plc shares slumped the most in intraday trading since 2008, wiping about 5.7 billion pounds ($7.25 billion) off the drugmaker's market value, after it agreed to buy Tesaro Inc. for $5.1 billion on Monday.
Bloomberg first reported Tesaro was looking to sell itself in November. An analyst at Piper Jaffray said at the time a deal would be a “headscratcher,” given the headwinds facing Tesaro's drug Zejula, as well as an immuno-oncology portfolio “that is still not ready for prime time.” Glaxo's $75 per share offer is a 62 percent premium to Tesaro's Friday close.
Glaxo shares were down about 8 percent at 3:10 p.m. in London. Tesaro was up 59 percent at $73.77.
To contact the reporters on this story: Adveith Nair in London at anair29@bloomberg.net;David Merritt in London at dmerritt1@bloomberg.net
To contact the editors responsible for this story: Kenneth Wong at kwong11@bloomberg.net, Adveith Nair
©2018 Bloomberg L.P.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
